GLP-1 & Healthcare Disruption ETF Report: Winners and Losers in the New Health Economy

The rise of GLP-1 drugs (Ozempic, Wegovy, Mounjaro) is reshaping entire industries. From pharma pipelines to food & beverage demand, the ripple effects are massive.This guide helps you invest around the trend with ETFs: 💊 Top Healthcare & Biotech ETFs with GLP-1 exposure 📉 Consumer staples & beverage ETFs at risk 📊 Performance scorecards for pharma/biotech vs. staples 🏥 Case studies on health-driven sector rotation 📈 Portfolio strategies to balance growth vs. disruption Bonus: Canva-ready infographic comparing “Winners vs. Losers” for quick reference.File Deliverables PDF guide (20 pages) Infographic (PNG/PDF)